Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing the Efficacy and Safety of Bimagrumab Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction (ACTIVATE-HFpEF)
NCT07920887 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing the Efficacy and Safety of Bimagrumab Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction (ACTIVATE-HFpEF)
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- November 30, 2029
- Enrollment
- 540 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
diastolic heart failure, heart failure, diastolic, heart failure, normal ejection fraction, heart failure, preserved ejection fraction
Arms
As registered; 4 arms.
-
Bimagrumab Dose 1
Participants will receive bimagrumab subcutaneously (SC)
-
Bimagrumab Dose 2
Participants will receive bimagrumab SC
-
Placebo 1
Participants will receive placebo SC
-
Placebo 2
Participants will receive placebo SC
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change from Baseline in the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS)
Lead sponsor's other trials
Eli Lilly and Company, most recent start first.
+2,102 more trials See the organization page
Similar trials
Same condition (Heart Failure, Diastolic) and phase, most recent start first.
+13 more trials See the condition page